KR970032889A - Liposomes Containing Peptide Antigens of Hepatitis B Virus - Google Patents

Liposomes Containing Peptide Antigens of Hepatitis B Virus Download PDF

Info

Publication number
KR970032889A
KR970032889A KR1019950065412A KR19950065412A KR970032889A KR 970032889 A KR970032889 A KR 970032889A KR 1019950065412 A KR1019950065412 A KR 1019950065412A KR 19950065412 A KR19950065412 A KR 19950065412A KR 970032889 A KR970032889 A KR 970032889A
Authority
KR
South Korea
Prior art keywords
phospholipid
hepatitis
virus
liposomes containing
sensitive liposome
Prior art date
Application number
KR1019950065412A
Other languages
Korean (ko)
Other versions
KR0173366B1 (en
Inventor
이기영
장진수
정현용
최명준
황유경
조성유
박용식
정홍석
문홍모
Original Assignee
허영섭
재단법인 목암생명공학연구소
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 허영섭, 재단법인 목암생명공학연구소 filed Critical 허영섭
Priority to KR1019950065412A priority Critical patent/KR0173366B1/en
Publication of KR970032889A publication Critical patent/KR970032889A/en
Application granted granted Critical
Publication of KR0173366B1 publication Critical patent/KR0173366B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

본 발명은 B형 간염 바이러스 유래의 펩타이드 항원을 리포좀(liposome)에 포획하고 면역시켜, B형 간염 바이러스에 특이적인 세포독성 T 임파구(cytotoxic T ilmphocyte : CTL)의 생성을 유도하는 세포성 면역(cellualr ilmmunity)을 야기시키는 리포좀에 관한 것이다. 이러한 리포좀은 HBV 관련 질환의 예방과 치료에 이용될 수 있을 것이다.The present invention captures and immunizes peptide antigens derived from hepatitis B virus to liposomes, thereby inducing cellular immunity to induce the production of cytotoxic T lymphocytes (CTLs) specific for hepatitis B virus. to liposomes causing ilmmunity). Such liposomes may be used for the prevention and treatment of HBV related diseases.

Description

B형 간염 바이러스의 펩타이드 항원을 함유하는 리포좀Liposomes Containing Peptide Antigens of Hepatitis B Virus

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

Claims (5)

하기와 같은 아미노산 서열을 포함하는 HBV 유래의 펩타이드 항원 및 그의 기능적 등가물 1종 이상과 인지질을 몰 비율로 1:5 내지 1:25가 되도록 펩티이드 항원을 함유하는 pH에 민감한 리포좀 : LLDPRVRGL, LVLLDYQGML, VLLDYQGML, FLPSDFFPSI, CLTFGRETV, VLEYLVSFGV (상기에서, 아미노산 서열은 IUPAC-IUB)의 명명법에 따라 기재하였다).PH-sensitive liposomes containing a peptide antigen such that the peptide antigen derived from HBV and one or more functional equivalents thereof and a phospholipid in a molar ratio of 1: 5 to 1:25 comprising the following amino acid sequence: LLDPRVRGL, LVLLDYQGML, VLLDYQGML, FLPSDFFPSI, CLTFGRETV, VLEYLVSFGV (wherein the amino acid sequence is described according to the nomenclature of IUPAC-IUB). 제 1항에 있어서, 펩타이드 항원은 세포독성 T 임파구의 생성을 유도하는 것을 특징으로 하는 pH에 민감한 리포좀.The pH sensitive liposome according to claim 1, wherein the peptide antigen induces production of cytotoxic T lymphocytes. 제 1항에 있어서, 인지질은 포스파티딜에탄올아민-β-올레일-γ-팔미토일(phosphatidyl-ethanolamine-β-oleoyl-γ-palmitoyl)과 콜레스케롤 헤미석시네이트(cholesterol hemisuccinate)를 몰비율로 6:4내지 8:2로 혼합한 것을 특징으로 하는 pH에 민감한 리포좀.The phospholipid of claim 1, wherein the phospholipid comprises phosphatidylethanolamine-β-oleyl-γ-palmitoyl and cholesterol hemisuccinate in a molar ratio. A pH sensitive liposome, characterized by mixing 6: 4 to 8: 2. 제 3항에 있어서, 인지질은 1몰%의 단일인산화 지질 A(monophosphoryl lipd A)추가로 포함하는 것을 특징으로 하는 pH에 민감한 리포좀.4. The pH-sensitive liposome according to claim 3, wherein the phospholipid further comprises 1 mol% of monophosphoryl lipd A. 제 1항에 있어서, 인지질의 포스파티질에탄올아민-β-올레일-γ-팔미토일(phosphatidyl-ethanolamine-β-oleoyl-γ-palmitoyl) 함량은 50% 이상인 것을 특징으로 하는 pH에 민감한 리포좀.The pH sensitive liposome according to claim 1, wherein the phosphatidylethanolamine-β-oleyl-γ-palmitoyl content of the phospholipid is 50% or more. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019950065412A 1995-12-29 1995-12-29 Liposome comprising hbv-derived peptide antigen KR0173366B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1019950065412A KR0173366B1 (en) 1995-12-29 1995-12-29 Liposome comprising hbv-derived peptide antigen

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1019950065412A KR0173366B1 (en) 1995-12-29 1995-12-29 Liposome comprising hbv-derived peptide antigen

Publications (2)

Publication Number Publication Date
KR970032889A true KR970032889A (en) 1997-07-22
KR0173366B1 KR0173366B1 (en) 1999-02-01

Family

ID=19447030

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950065412A KR0173366B1 (en) 1995-12-29 1995-12-29 Liposome comprising hbv-derived peptide antigen

Country Status (1)

Country Link
KR (1) KR0173366B1 (en)

Also Published As

Publication number Publication date
KR0173366B1 (en) 1999-02-01

Similar Documents

Publication Publication Date Title
FI932561A (en) Protein with intact epithelium and pharyngeal protein
NZ237611A (en) Variant hepatitis b surface antigen
ATE273320T1 (en) FUSOGENIC LIPOSOMES
NO940218D0 (en) Induction of cytotoxic T lymphocyte response
KR900013979A (en) Immunogenic Regions of the Human Papillomavirus Type 16 E7 Protein
WO2002020554A3 (en) Hiv peptides from conserved regions in gag p17 and 924 and their application in e.g. vaccines
NZ510419A (en) A vaccine adjuvant that is an oil-in-water immunoslimulant emulsion
HK1013849A1 (en) An augmented western blot format and immunoassay for detection of viral antibodies
MX9603182A (en) Hepatitis b vaccine.
WO1995016040A3 (en) Immunofluorescence assay for the detection of antibodies using recombinant antigens in insoluble form
KR970032889A (en) Liposomes Containing Peptide Antigens of Hepatitis B Virus
KR970032891A (en) Liposomes Containing Peptide Antigens of Hantan Bacillus
AP9100296A0 (en) Peptides and analogues and mixtures thereof for detecting antibodies to HTLV-1 and HTLV11 viruses.
KR970032888A (en) Liposomes Containing Peptide Antigens of Hepatitis C Virus
DE69420970T2 (en) Vaccine preparations
KR960010021A (en) Liposomes Containing Peptide Antigens
EP0379295A3 (en) Anti-tryptase antibody and composition for treatment of aids using the same
DE69328488D1 (en) PEPTIDES, ANALOGS AND THEIR MIXTURES FOR DETECTING AND GENERATING ANTIBODIES AGAINST THE E1 AND E2 PROTEINS OF RUBELLA VIRUS
KR970032892A (en) Liposomes Containing Peptide Mixed Antigens of Human Immunodeficiency Virus
FR2737209B1 (en) PEPTIDE CAPABLE OF BEING RECOGNIZED BY ANTIBODIES RECOGNIZING THE C33 ANTIGEN OF HEPATITIS C VIRUS
KR970032893A (en) Liposomes containing polypeptides linked to peptide antigens of different origin
ATE200678T1 (en) UROGENITAL CARCINOMA TLP PEPTIDE COMPLEX AND DERIVED ANTIBODIES
KR970032894A (en) Liposomes that induce mucosal immunity
DE494825T1 (en) SYNTHETIC PEPTIDES OF HEPATITIS B VIRUS HBC ANTIGEN.
EP0309898A3 (en) Method for the induction of a cytotoxic t cell response

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20081001

Year of fee payment: 11

LAPS Lapse due to unpaid annual fee